Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations

Immunovant CEO Peter Salzmann sold 9,095 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On October 16, 2024, Peter Salzmann, the CEO of Immunovant, Inc., sold 9,095 shares of common stock.
• The sale was executed at a weighted average price of $28.79 per share.
• The shares were sold to cover tax withholding obligations associated with the vesting of 15,240 restricted stock units (RSUs) on October 12, 2024.
• Following the transaction, Salzmann still beneficially owns 994,789 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't indicate any significant positive or negative sentiment. It's a neutral event.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The 'sell to cover' mechanism is a standard practice to manage tax obligations associated with equity compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates